Loading...
XKRX
226950
Market cap455mUSD
Jun 16, Last price  
45,600.00KRW
1D
4.71%
1Q
-1.08%
IPO
43.40%
Name

OliX Pharmaceuticals Inc

Chart & Performance

D1W1MN
XKRX:226950 chart
P/E
—
P/S
110.32
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.38%
Rev. gr., 5y
38.10%
Revenues
5.68b
-66.73%
907,617,931391,900,557243,966,300302,000,0001,130,327,0532,474,272,0923,674,356,7659,320,323,64517,064,275,4405,677,151,910
Net income
-40.66b
L+112.85%
-2,981,507,333-3,655,601,087-5,163,924,704-7,742,007,380-14,352,745,072-19,384,552,650-29,714,663,862-19,495,352,386-19,101,696,120-40,658,699,590
CFO
-28.04b
L+32.48%
-3,448,353,860-3,448,577,949-4,787,060,999-8,359,441,717-10,733,212,800-3,759,218,608-19,053,575,334-30,682,858,180-21,168,432,070-28,044,990,530
Dividend
Mar 15, 20220.285 KRW/sh
Earnings
Aug 11, 2025

Profile

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
URL
http://www.olixpharma.com/
IPO date
Jul 18, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,677,152
-66.73%
17,064,275
83.09%
9,320,324
153.66%
Cost of revenue
23,067,664
24,813,167
21,373,201
Unusual Expense (Income)
NOPBT
(17,390,512)
(7,748,892)
(12,052,877)
NOPBT Margin
Operating Taxes
(411,968)
932,072
(994,903)
Tax Rate
NOPAT
(16,978,544)
(8,680,964)
(11,057,974)
Net income
(40,658,700)
112.85%
(19,101,696)
-2.02%
(19,495,352)
-34.39%
Dividends
Dividend yield
Proceeds from repurchase of equity
474,650
(166,045)
BB yield
-0.23%
0.06%
Debt
Debt current
17,758,638
1,065,280
20,170,182
Long-term debt
22,185,022
42,287,775
23,825,820
Deferred revenue
2,617,552
2,831,259
Other long-term liabilities
1,282,454
5,016,213
248,694
Net debt
33,484,936
(6,052,318)
(44,684,519)
Cash flow
Cash from operating activities
(28,044,991)
(21,168,432)
(30,682,858)
CAPEX
(13,909,522)
(8,826,201)
(2,534,613)
Cash from investing activities
973,556
34,366,402
(54,763,807)
Cash from financing activities
18,541,377
(6,110,382)
56,048,065
FCF
(23,734,413)
(16,077,618)
(16,764,646)
Balance
Cash
12,414,378
25,924,618
61,871,744
Long term investments
(5,955,655)
23,480,754
26,808,777
Excess cash
6,174,866
48,552,159
88,214,505
Stockholders' equity
(157,931,824)
(106,840,963)
(74,162,303)
Invested Capital
216,879,349
204,168,029
183,614,993
ROIC
ROCE
EV
Common stock shares outstanding
16,919
14,429
13,703
Price
19,260.00
32.10%
14,580.00
-28.35%
20,350.00
-50.37%
Market cap
325,855,356
54.89%
210,379,646
-24.56%
278,859,306
-50.30%
EV
359,964,052
205,245,631
235,969,954
EBITDA
(14,764,333)
(5,106,944)
(10,080,031)
EV/EBITDA
Interest
4,661,251
3,491,742
2,930,301
Interest/NOPBT